<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article291</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/NAVIGATE_ESUS" style="display:block; margin-bottom:10px;">NAVIGATE ESUS Original</a></li>
<h2><strong>NAVIGATE ESUS</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>
<br/>
The New England Journal of Medicine. 2018.<br/>
<br/>
<h2><strong>Clinical Question:</strong></h2><br/>
Does rivaroxaban, an oral factor Xa inhibitor, reduce the risk of recurrent stroke compared to aspirin in patients with recent embolic strokes of undetermined source?<br/>
<br/>
<h2><strong>Bottom Line:</strong></h2><br/>
Rivaroxaban did not reduce the risk of recurrent stroke compared to aspirin in patients with recent embolic strokes of undetermined source and was associated with a higher risk of bleeding.<br/>
<br/>
<h2><strong>Major Points:</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines:</strong></h2><br/>
<hr/><br/>
<h2><strong>Guidelines for secondary prevention of stroke in the context of embolic strokes of undetermined source would need to reflect the results of this trial.</strong></h2><br/>
<br/>
<h2><strong>Design:</strong></h2><br/>
Randomized, double-blind, event-driven, phase 3 trial at 459 centers in 31 countries.<br/>
<br/>
<h2><strong>Population:</strong></h2><br/>
Patients with recent ischemic stroke of undetermined source without arterial stenosis, cardioembolic source, or other determined causes. 7213 participants were enrolled.<br/>
<br/>
Inclusion Criteria:<br/>
- Ischemic stroke without a clear source<br/>
- Absence of proximal arterial stenosis, known cardioembolic source, or lacune<br/>
- Stroke occurrence between 7 days and 6 months prior to screening<br/>
<br/>
Exclusion Criteria:<br/>
- History of atrial fibrillation<br/>
- Severe stroke (modified Rankin score â‰¥4)<br/>
- Indication for anticoagulation or antiplatelet therapy beyond study parameters<br/>
<br/>
<h2><strong>Interventions:</strong></h2><br/>
- Rivaroxaban (15 mg daily)<br/>
- Aspirin (100 mg daily)<br/>
<br/>
<h2><strong>Outcomes:</strong></h2><br/>
Primary Efficacy Outcomes:<br/>
- Recurrence of ischemic or hemorrhagic stroke or systemic embolism<br/>
- Rivaroxaban group: 172 patients (5.1% annualized rate)<br/>
- Aspirin group: 160 patients (4.8% annualized rate)<br/>
<br/>
Primary Safety Outcomes:<br/>
- Major bleeding events<br/>
- Rivaroxaban group: 62 patients (1.8% annualized rate)<br/>
- Aspirin group: 23 patients (0.7% annualized rate)<br/>
<br/>
<h2><strong>Criticisms:</strong></h2><br/>
- The trial was stopped early due to the lack of benefit and increased bleeding risk with rivaroxaban.<br/>
- A majority of the included patients had minor residual deficits at trial entry (median NIHSS score of 1).<br/>
<br/>
<h2><strong>Funding:</strong></h2><br/>
Bayer and Janssen Research and Development.<br/>
<br/>
<h2><strong>Further Reading:</strong></h2><br/>
- Full trial manuscript as published in The New England Journal of Medicine<br/>
- Other relevant trials on secondary stroke prevention and the use of anticoagulation in embolic strokes of undetermined source
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
